In a phase I study in unselected STS patients [56], the combination was reasonably well tolerated, in agreement with our findings in the SS xenograft, suggesting that the MEK inhibitor could be safely combined with pazopanib for treatment of patients with NRAS mutated SS. This evidence concerns the gene MAP2K7 and synovial sarcoma.